Expertise in
7
conditions

Dr. Mark A. Goldstein

Internal Medicine
NCHMD Inc Moorings Park Concierge
132 Moorings Park Dr, 
Naples, FL 
Expertise in
7
conditions
NCHMD Inc Moorings Park Concierge
132 Moorings Park Dr, 
Naples, FL 

Overview

Mark Goldstein is a primary care provider, practicing in Internal Medicine in Naples, Florida.

Dr. Goldstein is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Idiopathic Edema, Magnesium Deficiency, Gitelman Syndrome, and Alzheimer's Disease.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 29 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

NCHMD Inc Moorings Park Concierge
132 Moorings Park Dr, Naples, FL 34105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2025
Intervention Type: Drug
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Nicotine Transdermal Patch
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: CT1812
Study Phase: Phase 2
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug, Other
Study Drug: Donanemab
Study Phase: Phase 2
View 9 Less Clinical Trials

2 Total Publications

Evaluation of c-Abl inhibitor vodobatinib in subjects with early Parkinson's disease: a phase 2, randomized, double-blind, placebo-controlled study.
Evaluation of c-Abl inhibitor vodobatinib in subjects with early Parkinson's disease: a phase 2, randomized, double-blind, placebo-controlled study.
Journal: NPJ Parkinson's disease
Published: July 11, 2025
Similar Doctors
Expertise in
112
conditions
Dr. Pavan K. Anand
Internal Medicine
Expertise in
112
conditions
Dr. Pavan K. Anand
Internal Medicine
Before you request

Pavan K Anand MD PA

599 Tamiami Trl N Ste 210, 
Naples, FL 
 (4.7 miles away)
239-435-1999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Pavan Anand is a primary care provider, practicing in Internal Medicine in Naples, Florida. Dr. Anand is highly rated in 112 conditions, according to our data. His clinical expertise encompasses Mitochondrial Complex V Deficiency, Cytochrome C Oxidase Deficiency, High Cholesterol, and Abdominal Obesity Metabolic Syndrome. Dr. Anand is currently accepting new patients.

Expertise in
30
conditions
Dr. Bryan C. Murphey
Internal Medicine
Expertise in
30
conditions
Dr. Bryan C. Murphey
Internal Medicine

Nch Medical Group Internal Medicine-Health Park

11181 Health Park Blvd Ste 1165, 
Naples, FL 
 (4.7 miles away)
239-624-0320
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Bryan Murphey is a primary care provider, practicing in Internal Medicine in Naples, Florida. Dr. Murphey is highly rated in 30 conditions, according to our data. His clinical expertise encompasses High Cholesterol, Anemia, Hypothyroidism, and Glucocorticoid-Remediable Aldosteronism. Dr. Murphey is currently accepting new patients.

Expertise in
22
conditions
Dr. Brett E. Stanaland
Internal Medicine
Expertise in
22
conditions
Dr. Brett E. Stanaland
Internal Medicine

Brett E. Stanaland M.D. P.A.

1000 Goodlette Rd Ste 200, 
Naples, FL 
 (4.7 miles away)
239-434-6200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brett Stanaland is a primary care provider, practicing in Internal Medicine in Naples, Florida. Dr. Stanaland is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Allergic Rhinitis, Empyema, Grass Allergy, and Sinusitis. Dr. Stanaland is currently accepting new patients.

Frequently Asked Questions about Dr. Mark A. Goldstein

How do I make an appointment with Dr. Mark A. Goldstein?

You can book an appointment with Dr. Mark A. Goldstein by calling their office at 239-430-6391. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark A. Goldstein a top-rated expert for Idiopathic Edema?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark A. Goldstein is classified as an Advanced expert for Idiopathic Edema, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark A. Goldstein specialize in?

While Dr. Mark A. Goldstein is a Internal Medicine, they have specific expertise in Idiopathic Edema, Magnesium Deficiency, and Gitelman Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Mark A. Goldstein participate in research or clinical trials?

Yes. Dr. Mark A. Goldstein has published 2 articles and abstracts on conditions like Idiopathic Edema. You can view a list of Dr. Mark A. Goldstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark A. Goldstein accept my insurance?

Dr. Mark A. Goldstein accepts most major insurance plans, including Blue Cross Blue Shield and Independent Health. We recommend calling the office directly at 239-430-6391 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goldstein's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 45 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile